Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-β1 (TGF-β1) availability and inhibits hepatocarcinogenesis

Abstract

Background: Increased Galectin 3-binding protein (LGALS3BP) serum levels have been used to assess hepatic fibrosis stages and the severity of hepatocellular carcinoma (HCC). Considering the crucial role of transforming growth factor-β1 (TGF-β1) in the emergence of these diseases, the present study tested the hypothesis that LGALS3BP regulates the TGF-β1 signaling pathway.

Methods: The expression levels of LGALS3BP and TGFB1 were analyzed in patients with metabolic dysfunction-associated steatohepatitis (MASH) and HCC. Multiple omics techniques, such as RNA-sequencing, transposase-accessible chromatin-sequencing assay, and liquid chromatography-tandem mass spectrometry proteomics, were used to identify the regulatory mechanisms for the LGALS3BP-TGF-β1 axis. The effects of altered TGF-β1 signaling by LGALS3BP were investigated in conditional LGALS3BP-knockin and LGALS3BP-knockout mice.

Results: In patients with MASH and HCC, the levels of LGALS3BP and TGFB1 exhibited positive correlations. Stimulation of LGALS3BP by the inflammatory cytokine interferon α in HCC cells or ectopic overexpression of LGALS3BP in hepatocytes promoted the expression levels of TGFB1. Aggravated fibrosis was observed in the livers of hepatocyte-specific LGALS3BP-knockin mice, with increased TGFB1 levels. LGALS3BP directly bound to and assembled integrin αV, an integral mediator required for releasing active TGF-β1 from extracellular latent complex with the rearranged F-actin cytoskeleton. The released TGF-β1 activated JunB transcription factor, which in turn promoted the TGF-β1 positive feedback loop. LGALS3BP deletion in the hepatocytes downregulated TGF-β1 signaling and CCl₄ induced fibrosis. Moreover, LGALS3BP depletion hindered hepatocarcinogenesis by limiting the availability of fibrogenic TGF-β1.

Conclusion: LGALS3BP plays a crucial role in hepatic fibrosis and carcinogenesis by controlling the TGF-β1 signaling pathway, making it a promising therapeutic target in TGF-β1-related diseases.

Keywords

F-actin / FAK / hepatic carcinogenesis / Integrin αV / Interferon α / JunB / LGALS3BP / metabolic dysfuntion-associated steatohepatitis / tensile force, TGF-β1

References

[1] Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1): 6.

[2] Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018; 19(3): 222–232.

[3] Craig AJ, von Felden J, Garcia-Lezana T. Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020; 17(3): 139–152.

[4] Xu G, Xia Z, Deng F, Liu L, Wang Q, Yu Y, et al. Inducible LGALS3BP/90K activates antiviral innate immune responses by targeting TRAF6 and TRAF3 complex. PLoS Pathog. 2019; 15(8): e1008002.

[5] Loimaranta V, Hepojoki J, Laaksoaho O, Pulliainen AT. Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections. J Leukoc Biol. 2018; 104(4): 777–786.

[6] Laubli H, Alisson-Silva F. Stanczak MA, Siddiqui SS, Deng L, Verhagen A, et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 2014; 289(48): 33481–33491.

[7] Kono M, Nakamura Y, Oyama Y, Mori K, Hozumi H, Karayama M, et al. Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. Respir Med. 2016; 115: 46–52.

[8] Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One. 2018; 13(8): e0202226.

[9] Costa J, Pronto-Laborinho A. Pinto S, Gromicho M, Bonucci S, Tranfield E, et al. Investigating LGALS3BP/90 K glycoprotein in the cerebrospinal fluid of patients with neurological diseases. Sci Rep. 2020; 10(1): 5649.

[10] Iacobelli S, Natoli C, D’Egidio M, Tamburrini E, Antinori A, Ortona L. Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. J Infect Dis. 1991; 164(4): 819.

[11] Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, et al. LGALS3BP, lectin galactoside-bindin. soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl). 2013; 91(1): 83–94.

[12] Traini S, Piccolo E, Tinari N, Rossi C, La Sorda R, Spinella F, et al. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding solubl. 3 binding protein (LGALS3BP) antibody. Mol Cancer Ther. 2014; 13(4): 916–925.

[13] Capone E, Iacobelli S, Sala G. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. J Transl Med. 2021; 19(1): 405.

[14] Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2020; 26(3): 261–279.

[15] Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2018; 48(11): 872–881.

[16] Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996; 25(2): 212–217.

[17] Kittl EM, Hofmann J, Hartmann G, Sebesta C, Beer F, Bauer K, et al. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med. 2000; 38(3): 205–208.

[18] Gutmann C, Takov K, Burnap SA, Singh B, Ali H, Theofilatos K, et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun. 2021; 12(1): 3406.

[19] Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, et al. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C. PLoS One. 2016; 11(3): e0151828.

[20] Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3: 1065.

[21] Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol. 2020; 26(21): 2864–2876.

[22] Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med. 2001; 39(10): 961–965.

[23] Correale M, Giannuzzi V, Iacovazzi PA, Valenza MA, Lanzillotta S, Abbate I, et al. Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res. 1999; 19(4C): 3469–3472.

[24] Derynck R, Turley SJ, Akhurst RJ. TGFbeta biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021; 18(1): 9–34.

[25] Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022; 21(1): 104.

[26] Meng XM, Nikolic-Paterson DJ. Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6): 325–338.

[27] Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013; 13(11): 788–799.

[28] Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999; 96(3): 319–328.

[29] Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1 -an intimate relationship. Eur J Cell Biol. 2008; 87(8-9): 601–615.

[30] Robertson IB, Rifkin DB. Regulation of the Bioavailability of TGF-beta and TGF-beta-Related Proteins. Cold Spring Harb Perspect Biol. 2016; 8(6): a021907.

[31] Hong CS, Park MR, Sun EG, Choi W, Hwang JE, Bae WK, et al. Gal-3BP Negatively Regulates NF-kappaB Signaling by Inhibiting the Activation of TAK1. Front Immunol. 2019; 10: 1760.

[32] Uehara T, Pogribny IP, Rusyn I. The DEN and CCl(4) -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc. 2021; 1(8): e211.

[33] Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. 2010; 10: 79.

[34] Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010; 140(2): 197–208.

[35] Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021; 1(3): e90.

[36] Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010; 38(4): 576–589.

[37] Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC. TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer. 2012; 12: 26.

[38] Santibanez JF, Obradovic H, Kukolj T, Krstic J. Transforming growth factor-beta, matrix metalloproteinases, and urokinase-typ. plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Dev Dyn. 2018; 247(3): 382–395.

[39] Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF-beta signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024; 9(1): 61.

[40] Alvarez MD, Ronco MT, Ochoa JE, Monti JA, Carnovale CE, Pisani GB, et al. Interferon α-induced apoptosis on rat preneoplastic liver is mediated by hepatocytic transforming growth factor β. Hepatology. 2004; 40(2): 394–402.

[41] Alvarez Mde L, Quiroga AD, Parody JP, Ronco MT, Frances DE, Carnovale CE, et al. Cross-talk between IFN-alpha and TGF-beta1 signaling pathways in preneoplastic rat liver. Growth Factors. 2009; 27(1): 1–11.

[42] Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem. 1998; 273(33): 21145–21152.

[43] Sundqvist A, Morikawa M, Ren J, Vasilaki E, Kawasaki N, Kobayashi M, et al. JUNB governs a feed-forward network of TGFbeta signaling that aggravates breast cancer invasion. Nucleic Acids Res. 2018; 46(3): 1180–1195.

[44] Hariyanto NI, Yo EC, Wanandi SI. Regulation and Signaling of TGF-beta Autoinduction. Int J Mol Cell Med. 2021; 10(4): 234–247.

[45] Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998; 394(6696): 909–913.

[46] Cirkel GA, Kerklaan BM, Vanhoutte F, Van der Aa A, Lorenzon G, Namour F, et al. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. Invest New Drugs. 2016; 34(2): 184–192.

[47] Huntington KE, Carlsen L, So EY, Piesche M, Liang O, El-Deiry WS. Integrin/TGF-beta1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity. Pharmaceuticals (Basel). 2022; 15(5): 618.

[48] Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010; 11(5): 353–365.

[49] Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023; 8(1): 1.

[50] Dong X, Zhao B, Iacob RE, Zhu J, Koksal AC, Lu C, et al. Force interacts with macromolecular structure in activation of TGF-beta. Nature. 2017; 542(7639): 55–59.

[51] Grassadonia A, Graziano V, Pagotto S, Veronese A, Giuliani C, Marchisio M, et al. Tgf-beta1 transcriptionally promotes 90K expression: possible implications for cancer progression. Cell Death Discov. 2021; 7(1): 86.

[52] Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med. 2020; 12(572): eaba4448.

[53] Ikawa-Yoshida A, Matsuo S, Kato A, Ohmori Y, Higashida A, Kaneko E, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol. 2017; 98(4): 221–233.

[54] Tokinoya K, Sekine N, Aoki K, Ono S, Kuji T, Sugasawa T, et al. Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model. Mol Med Rep. 2021; 23(3): 210.

[55] Coffey RJ, Jr., Kost LJ, Lyons RM, Moses HL, LaRusso NF. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest. 1987; 80(3): 750–757.

[56] Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol. 2010; 22(9): 1066–1073.

[57] Yang B, Zhang J, Sun L, Huang T, Kong Y, Li L, et al. Mapping Novel Biomarkers of Liver Injury by Tissue Proteomic Analysis. ACS Omega. 2021; 6(10): 7127–7138.

[58] Baker ES, Burnum-Johnson KE. Jacobs JM, Diamond DL, Brown RN, Ibrahim YM, et al. Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics. 2014; 13(4): 1119–1127.

[59] Luo M, Zhang Q, Hu Y, Sun C, Sheng Y, Deng C. LGALS3BP: A Potential Plasma Biomarker Associated with Diagnosis and Prognosis in Patients with Sepsis. Infect Drug Resist. 2021; 14: 2863–2871.

[60] Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010; 11(2): 97–105.

[61] Conroy KP, Kitto LJ, Henderson NC. alphav integrins: key regulators of tissue fibrosis. Cell Tissue Res. 2016; 365(3): 511–519.

[62] Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov. 2022; 21(1): 60–78.

[63] Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021; 6(1): 153.

[64] Hannah WN, Jr., Torres DM, Harrison SA. Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. Gastroenterol Hepatol (N Y). 2016; 12(12): 756–763.

[65] Tian Z, Xu C, Yang P, Lin Z, Wu W, Zhang W, et al. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Front Immunol. 2022; 13: 984728.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.